DBV Technologies (NASDAQ:DBVT) Price Target Cut to $47.00 by Analysts at Citizens Jmp

DBV Technologies (NASDAQ:DBVT) had its price objective decreased by research analysts at Citizens Jmp from $55.00 to $47.00 in a report released on Thursday, Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp‘s target price would indicate a potential upside of 354.11% from the company’s current price.

A number of other equities research analysts also recently weighed in on DBVT. Cantor Fitzgerald reiterated an “overweight” rating on shares of DBV Technologies in a research note on Thursday, September 10th. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a research note on Thursday, October 15th. Wall Street Zen cut shares of DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of DBV Technologies in a report on Thursday. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.50.

DBV Technologies Stock Down 2.8%

Shares of DBVT stock traded down $0.30 during mid-day trading on Thursday, reaching $10.35. The stock had a trading volume of 616,049 shares, compared to its average volume of 317,838. DBV Technologies has a one year low of $8.63 and a one year high of $26.18. The firm has a market cap of $650.81 million, a PE ratio of -2.96 and a beta of -1.04. The firm’s 50 day simple moving average is $11.71 and its 200 day simple moving average is $17.00.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Wednesday, October 28th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.41). The firm had revenue of $1.60 million for the quarter, compared to the consensus estimate of $0.58 million. DBV Technologies had a negative net margin of 3,506.53% and a negative return on equity of 119.33%. Sell-side analysts forecast that DBV Technologies will post -2.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

A number of hedge funds have recently modified their holdings of the stock. Royal Bank of Canada grew its position in DBV Technologies by 167.1% in the first quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock valued at $98,000 after acquiring an additional 2,928 shares during the period. Vontobel Holding Ltd. bought a new position in shares of DBV Technologies during the third quarter valued at $144,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of DBV Technologies by 170.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 21,600 shares of the company’s stock valued at $249,000 after acquiring an additional 13,600 shares during the period. Personal CFO Solutions LLC bought a new position in shares of DBV Technologies during the first quarter valued at $264,000. Finally, Cetera Investment Advisers boosted its stake in shares of DBV Technologies by 93.4% in the 1st quarter. Cetera Investment Advisers now owns 25,358 shares of the company’s stock valued at $530,000 after purchasing an additional 12,243 shares in the last quarter. 71.74% of the stock is owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies’ lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.